Thermo Fisher Scientific Inc. (TMO) — BATS 19/100 — 2026-07-23

Listen to the earnings call audio for free on StockAnalysis

Summary based on Thermo Fisher Scientific Inc. earnings call on 2026-07-23

BotFlo AI Transformation Score for $TMO: 19 (19/100)

Sector AI Transformation Score for $TMO: 0 (0/50)

Presentation

(1/7) Outstanding Q2 results and strengthening end markets
• 📈 Revenue grew 10% to $11.99 billion with adjusted operating income up 15% to $2.73 billion, margin expansion of 90 basis points to 22.8%, and adjusted EPS up 13% to $6.03.
• 🧪 Customer activity strengthened across Pharma and Biotech, Academic and Government, Industrial and Applied, and Diagnostics and Health Care, with mid- or low-single-digit growth by end market.
• 🎯 Excellent execution and the proven growth strategy helped capitalize on opportunities and drive share gain.

(2/7) High-impact innovation including AI-driven mass spectrometry
• 🤖 At ASMS the company launched next-generation Orbitrap platforms and AI-driven capabilities, highlighted by Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers.
• 🧬 An expanding suite of AI-powered software delivers smarter workflows and accelerates proteomics research alongside the Vanquish Amplify UHPLC system.
• 🔬 Life Science Solutions introduced the Applied Biosystems PowerFlex thermal cycler to improve PCR workflow flexibility, productivity, and reproducibility.

(3/7) Trusted partner status, collaborations, and commercial engine
• 🏭 Thermo Fisher opened a flagship U.S. bioprocess design center in Massachusetts to co-innovate with pharma and biotech on development and manufacturing.
• 🤝 A strategic collaboration with Precision Health Research Singapore combines Olink proteomics and Orbitrap Astral to advance population-scale precision medicine.
• 🚀 These engagements help customers solve challenges, accelerate innovation, and strengthen Thermo Fisher’s leadership position.

(4/7) Capital deployment, acquisitions, and microbiology divestiture
• 💼 Clario integration is progressing smoothly with strong Q2 performance and a building funnel of revenue synergies after the late-March close.
• 🔧 The Filtration and Separation business continues strong performance with positive customer feedback and smooth integration.
• 💰 An agreement to divest the microbiology business is expected to close in Q3, with anticipated net proceeds used to repurchase $1 billion of shares in Q2.

(5/7) PPI Business System, AI deployment, and CSR updates
• ⚙️ PPI enabled strong profitability and free cash flow while improving quality, productivity, and customer allegiance.
• 🤖 The company is actively deploying AI across the organization to further accelerate PPI’s impact.
• 🌱 CSR progress includes the Net Zero roadmap, more renewable electricity, additional Zero Waste sites, and STEM programs reaching more than 185,000 students annually.

(6/7) Raised full-year 2026 guidance
• 📈 Full-year revenue guidance was raised to $47.4 to $48.1 billion, or 6% to 8% reported growth, with organic growth expected at about 4% at the upper end of the 3% to 4% range.
• 💵 Adjusted EPS guidance increased to $24.93 to $25.33, representing 9% to 11% growth and a $0.25 midpoint raise.
• ✅ Q2 delivered a clean beat with 5% organic revenue growth and 13% adjusted EPS growth, leaving the company well positioned for 2026.

(7/7) CFO financial detail, segments, and guidance bridge
• 📊 Q2 was about $300 million and $0.30 EPS ahead of prior guidance on stronger organic growth, acquisitions including Clario, FX, cost productivity, and volume leverage.
• 🧩 Segment organic growth was 3% in Life Sciences Solutions, 7% in Analytical Instruments, 5% in Specialty Diagnostics, and 5% in Laboratory Products and Biopharma Services.
• 🧭 Updated guide embeds ~4% organic growth, 80 bps AOI margin expansion, $1.6 billion acquisition revenue and $0.32 EPS, $200 million net divestiture revenue hit, and $6.9–$7.4 billion free cash flow.

Q&A

(1/9) Q&A: What drove the broad-based beat and strengthening end markets into the second half?
• 📈 Customer activity picked up across end markets in Q2 as expected versus 2025 levels, with encouraging progression in pharma and biotech including biotech spending.
• 💊 Pharma and biotech, about 60% of revenue, is progressing nicely and is the primary driver of the modest second-half organic outlook increase.
• 📅 First-half organic growth of 3% steps up to 4% in the second half with similar Q3 and Q4 phasing and no meaningful change versus original quarterly assumptions.

(2/9) Q&A: Incremental color on PPD, Clario, and Patheon services performance?
• 🧪 Clinical research had an excellent quarter with strong organic growth in revenue and authorizations as market conditions improve.
• 🩺 Clario’s first full ownership quarter was very strong on authorizations, revenue, and earnings, helping raise full-year acquisition contribution.
• 🏭 Accelerated drug development is compelling for biotech, while Patheon saw modest Q2 growth with a stronger second half tied to shipping and reshoring wins.

(3/9) Q&A: Where else is the back-half outlook better across the portfolio?
• 💊 The forward organic increase is really driven by pharma biotech after embedding the full Q2 beat.
• 🏫 Academic and government returned to growth with the U.S. slightly positive, but the outlook for that market was not raised amid ongoing stabilization.
• 🔍 Management will watch whether positive academic and government trends sustain before treating them as a new run-rate.

(4/9) Q&A: Pharma biotech spending, inventory, tariffs, and channel dynamics?
• 📦 Q2 was a clean quarter with broad-based pharma biotech momentum; bioproduction, clinical research, and research and safety channel were strong, and biotech is picking up.
• 🏥 Health care market channel Q1 headwinds and very strong Q2 should be averaged as representative first-half performance.
• 🛒 Research and safety channel strength reflects pharma biotech demand plus account wins and share gain more than academic as the big driver.

(5/9) Q&A: What drove Analytical Instruments strength and is China inflecting?
• 🤖 Analytical Instruments delivered high-single-digit growth across all three businesses, led by innovation including ASMS mass spectrometers and AI-enabled software plus strong high-end instrument adoption.
• 💻 Electron microscopy saw very strong growth and bookings in semiconductor and advanced materials, and a UHPLC launch bodes well for the future.
• 🇨🇳 China is about 7.5% of revenue and returned to low-single-digit growth on pharma biotech and industrial demand, while academic remains muted and China is not yet accretive to company organic growth.

(6/9) Q&A: Chemical Analysis strength and Pharma Services back-half phasing?
• ⚗️ Chemical Analysis growth was driven by higher commodity-price-sensitive industrial demand and increased safety and security applications such as radiation and explosive detection.
• 📉 Macro-sensitive parts are seeing better market conditions with solid team execution, though the business is not huge.
• 📅 Patheon second half steps up meaningfully versus low-single-digit first half on production schedules, but that does not imply Q4 grows over Q3.

(7/9) Q&A: Bioproduction above-market growth and large-pharma tone amid IRA, MFN, and AI noise?
• 🧫 Bioproduction is well positioned across upstream and downstream, including media, single-use, purification, and filtration via Solventum, with strong demand and capacity increases.
• 💬 Large-pharma conversations focus on accelerating pipelines productively with Thermo Fisher as a trusted partner, and tone is quite positive.
• 🧭 Customers feel they can navigate IRA, MFN, and tariffs successfully, making it an encouraging time to serve that base.

(8/9) Q&A: Where is academic and government in the cycle and what is PPD visibility?
• 🏫 Academic and government grew low single digits, led by chromatography and mass spectrometry adoption globally, with strong Europe and a U.S. return to growth.
• ⏳ Management is encouraged but not calling a new trend until activity is more broad-based; funding flow is improving and the market is slowly stabilizing.
• 📋 Biotech authorizations have been strong for several quarters with roughly a six-month lag to revenue; clinical research is having the good year expected, with strong Clario customer interest.

(9/9) Q&A: Bioprocessing competitive dynamics on downstream, resins, and new portfolio?
• 🏆 DynaDrive single-use bioreactors are increasingly standardized across CDMOs and adopted by innovators, supporting efficient production and follow-on consumables.
• 🧪 The resin business is smaller but winning new molecules through technology differentiation.
• 🔍 Legacy 3M filtration technology plus Thermo Fisher commercial reach is driving more customer trials as a reliable supplier.